Tenosynovial Giant Cell Tumor — Variants & evidence

Tenosynovial Giant Cell Tumor — Variants & evidence · CancerIndex

Variants & evidence

Curated clinical evidence by variant and therapy

1 evidence items mapped to this entity or its descendants, grouped by molecular profile, then therapy. 50 items per page.

civicCuratedShowing 1–1 of 1 evidence items · levels, directions and significance as curated at the source; each row links to its CIViC record.

Therapy	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
CSF1 Overexpression1
Pexidartinib	Predictive	B	Supports Sensitivity Response	3	submitted	EID1969 23 patients were enrolled in the phase 2 extension study. The chosen phase 2 dose of PLX3397 was 1000 mg per day. 12/23 patients with tenosynovial giant-cell tumors had a partial response and 7 patien… (full text at CIViC) PMID 26222558 · Tap et al., 2015 · Open in CIViC	civic

Data updated 15 hours agoSource updated unknownsource: civic (CC0)

Evidence levels, directions and ratings are those assigned by CIViC curators. "Submitted" items have not completed curation review. This is not treatment guidance.